In HER2+ BC, the interaction between the immune system and the tumor is complex and dynamic, involving different HER2-targeted treatments with chemotherapy and hormonotherapy, which modulate the action of HR status and tumor biology [116]. The gene discussed is ERBB2; the disease is neoplasm.